Forty Seven, Inc.
DelistedCIK 1667633fmd_118RGAR9GTDP05PZ5MCPYN6W9SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2019, 13 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Total revenues | – | – | – | 16 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 |
| Research and development | 14 | 37 | 57 | 84 |
| Total operating expenses | 20 | 45 | 72 | 104 |
| Operating income | (20) | (45) | (72) | (89) |
| Interest and investment income | 0 | 0 | 2 | 3 |
| Income tax expense | – | – | 0 | 0 |
| Net income | (20) | (45) | (70) | (88) |